BOSTON & MONTREAL, June 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.

CAR-T therapy targeting TM4SF1 in aggressive bladder cancer (HV) histologic variant , offering hope for treatment-resistant ...

Scientists found a way to identify and possibly treat a mysterious type of bladder cancer that affects up to 1 in 4 cases.

A breakthrough in bladder cancer treatment at the University of California, Davis: multifunctional nanoparticles enhance ...

enGene Holdings shares were up 7% to $3.25 after the company said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to detalimogene voraplasmid.

DelveInsight's, “Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

“Pelvic floor therapy is like physical therapy to strengthen all the muscles and tissues in your pelvis that can become weak ...

With topical estrogen, the vaginal flora returns back to the premenopausal stage with less E. coli -- a common cause of ...

Bladder cancer can be a silent killer, often presenting few symptoms in its early stages. Learn about the disease, its early symptoms, and more.